Cardio Diagnostics Holdings (NASDAQ: CDIO), a precision cardiovascular medicine company leveraging artificial intelligence, recently featured in an episode of The BioMedWire Podcast. CEO and Co-Founder Dr. Meesha Dogan discussed the company's mission to improve cardiovascular disease prevention and early detection through its AI-driven platform that integrates epigenetics, genetics, and artificial intelligence.
During the podcast, Dogan highlighted Cardio Diagnostics' expansion into India through strategic partnerships with Aimil Ltd. and Dr. Lal PathLabs. This move aims to make the company's precision medicine tests accessible to a broader population, addressing the high burden of cardiovascular disease in the region. The India expansion represents a significant step in the company's global growth strategy.
Dogan also provided updates on the company's progress through the Medicare reimbursement process. She noted that the CPT coding and payment steps have been completed, while coverage determination is still underway. This milestone is crucial for Cardio Diagnostics as it seeks to ensure that its tests are reimbursed, making them more accessible to patients covered by Medicare.
The company's core technology, the Integrated Genetic-Epigenetic Engine, uses AI to analyze genetic and epigenetic markers to assess an individual's risk for cardiovascular disease. This approach aims to make prevention, detection, and management more personalized and precise, potentially improving patient outcomes and reducing healthcare costs associated with heart disease.
Cardio Diagnostics is positioning itself as a leader in the precision cardiovascular medicine space. The company's focus on leveraging AI and advanced genomics to address cardiovascular disease—the leading cause of death globally—underscores the importance of its work. The India expansion and progress in Medicare reimbursement are key indicators of the company's growth trajectory and its potential impact on public health.
For more information about Cardio Diagnostics and its latest news, visit the company's newsroom at https://ibn.fm/CDIO. The full press release about the podcast appearance can be accessed at https://ibn.fm/8DJcl.
